The use of amiodarone with HCV treatments and another direct acting antiviral can result in symptomatic bradycardia, or serious slowing of the heart.
The FDA is recommending healthcare professionals not prescribe Harvoni or Sovaldi combined with another direct acting antiviral, such as daclatasvir or Olysiom, and amiodarone.
More articles on gastroenterology:
PENTAX Medical names new America’s president & chief marketing officer
7 statistics on Match Day for GI
7 things for gastroenterologists to know for today – March 20, 2015
